Compare ATO & BIIB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | ATO | BIIB |
|---|---|---|
| Founded | 1906 | 1978 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Oil/Gas Transmission | Biotechnology: Pharmaceutical Preparations |
| Sector | Utilities | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 27.2B | 24.2B |
| IPO Year | 1987 | 1991 |
| Metric | ATO | BIIB |
|---|---|---|
| Price | $169.21 | $177.23 |
| Analyst Decision | Hold | Buy |
| Analyst Count | 9 | 22 |
| Target Price | $169.50 | ★ $177.40 |
| AVG Volume (30 Days) | 920.0K | ★ 2.3M |
| Earning Date | 02-03-2026 | 02-11-2026 |
| Dividend Yield | ★ 2.39% | N/A |
| EPS Growth | ★ 9.22 | N/A |
| EPS | 7.46 | ★ 10.97 |
| Revenue | $4,702,755,000.00 | ★ $10,065,900,000.00 |
| Revenue This Year | $13.00 | $3.58 |
| Revenue Next Year | $10.35 | N/A |
| P/E Ratio | $22.47 | ★ $16.04 |
| Revenue Growth | ★ 12.91 | 4.77 |
| 52 Week Low | $136.16 | $110.04 |
| 52 Week High | $180.65 | $185.17 |
| Indicator | ATO | BIIB |
|---|---|---|
| Relative Strength Index (RSI) | 48.26 | 57.95 |
| Support Level | $167.30 | $175.00 |
| Resistance Level | $169.60 | $178.46 |
| Average True Range (ATR) | 2.19 | 3.50 |
| MACD | 0.25 | -0.44 |
| Stochastic Oscillator | 62.64 | 86.16 |
Atmos Energy is the largest publicly traded, fully regulated, pure-play natural gas utility in the United States, serving more than 3.3 million customers in Texas, Colorado, Kansas, Kentucky, Louisiana, Mississippi, Tennessee, and Virginia. About two thirds of its earnings come from Texas, where it distributes natural gas in northern Texas and owns an intrastate gas pipeline spanning several key shale gas formations and interconnected with five storage facilities.
Biogen is an established biopharmaceutical company focused on treatments for neurological diseases and rare diseases. Its declining multiple sclerosis franchise is its largest revenue generator and contributed 45% of total revenue in 2024. Biogen also generates significant revenue from its CD20 collaboration agreements with Roche (18% of total in 2024), which includes oncology drugs Rituxan and Gazyva and multiple sclerosis drug Ocrevus. Biogen's newer franchises include Spinraza (spinal muscular atrophy, with partner Ionis), Leqembi (Alzheimer's disease, collabroation revenue from its partner Eisai), Skyclarys (Friedreich's ataxia, Reata), Zurzuvae (postpartum depression, Sage), and Qalsody (amyotrophic lateral sclerosis, Ionis).